GM’s Cruise abandons Origin robotaxi, takes $583 million charge

Date:

Share post:


GM’s self-driving car subsidiary Cruise is scrapping plans to build the Origin  — a purpose-built robotaxi with no steering wheel or pedals — and will instead use the next-generation Chevrolet Bolt in its operations.

GM Chair and CEO Mary Barra told shareholders Tuesday the decision will “simplify their path to scale” and addresses the regulatory uncertainty faced with the Origin robotaxi because of its unique design. The per-unit costs will also be much lower, which will help Cruise optimize its resources, Barra said in the shareholder letter released alongside the company’s second-quarter earnings. 

GM reported a financial charge of $583 million in the second quarter that is tied to the non-cash write-off of Origin assets and other restructuring costs. The Cruise subsidiary had an operating loss of $1.14 billion in the second quarter that included a $605 million impairment charge. 

While Barra comments appear to hedge whether the Origin will return, the vehicle that GM once projected would number “in the tens of thousands,” is effectively dead. The decision also gives the next-generation Chevrolet Bolt another purpose. GM expects to begin production of the all-electric Chevrolet Bolt in 2025. A GM spokesperson declined to share when the autonomous version of the new Chevy Bolt would be on public roads. 

“GM and Cruise are optimizing resources to focus development of our next autonomous vehicle on the next generation Bolt instead of the Origin,” a GM spokesperson wrote in an emailed statement. “This shift creates a more cost-effective and scalable option for pursuing an autonomous future faster, while avoiding the uncertain path to regulatory compliance in the U.S. that could impede scaling of the Origin. The Origin does not include a steering wheel and brake pedals and uses campfire seating, a design that is currently not permitted.” 

The Origin — once the symbol of Cruise’s commercial future and a potential profit center for GM — has been on shaky ground since November 2023 when the company paused production of the purpose-built robotaxi after losing its permits to operate in California and voluntarily halting operations in other states. The California Department of Motor Vehicles, the agency that regulates autonomous vehicles in the state, suspended Cruise’s deployment and driverless testing permits in October after an incident in which a Cruise robotaxi dragged a pedestrian, who had initially been hit by a human-driven car.

Within two months of the incident, Cruise’s co-founder and CEO Kyle Vogt had resigned, about 24% of its workforce was laid off, and GM asserted more control over the embattled company. Since then, Cruise has hired Marc Whitten as its new CEO, created a chief safety officer position and slowly restarted testing in Dallas, Houston, and Phoenix. Cruise, a San Francisco-based startup acquired by GM in 2016, has not received approval from California regulators to relaunch operations there. 

Cruise unveiled the Origin in January 2020. It was the product of a multi-year collaboration with parent company GM and investor Honda that was designed for a ridesharing service. Cruise, and the nascent autonomous vehicle industry, was in a rosier, more ambitious place back then. The industry was beginning to consolidate and aggressive timelines for commercial driverless operations had slipped. But automakers and tech companies were still investing hundreds of millions of dollars into the effort. 

The effort to commercialize autonomous vehicle technology, and specifically robotaxis, has proven to be far costlier and time-consuming than many companies expected. Even after eliminating jobs and slashing costs, Cruise is still losing hundreds of millions of dollars every quarter. 



Source link

Lisa Holden
Lisa Holden
Lisa Holden is a news writer for LinkDaddy News. She writes health, sport, tech, and more. Some of her favorite topics include the latest trends in fitness and wellness, the best ways to use technology to improve your life, and the latest developments in medical research.

Recent posts

Related articles

OpenAI’s GPT-5 reportedly falling short of expectations

OpenAI’s efforts to develop its next major model, GPT-5, are running behind schedule, with results that don’t...

OpenAI announces new o3 model — but you can’t use it yet

Welcome back to Week in Review. This week, we’re looking at OpenAI’s last — and biggest —...

Google pushes back against DOJ’s ‘interventionist’ remedies in antitrust case

Google has offered up its own proposal in a recent antitrust case that saw the US Department...

If climate tech is dead, what comes next?

Humans have an innate desire to name things, but to be honest, we’re not always that good...

Hollywood angels: Here are the celebrities who are also star VCs

Becoming a venture capitalist has become the latest status symbol in Hollywood.  Everyone these days, from Olivia Wilde...

Meet Skyseed, a VC fund and incubator backing the Bluesky and AT Protocol ecosystem

On November 15, Peter Wang posted a message requesting ideas for a new incubator and fund to...

Sam Altman disputes Marc Andreessen’s description of AI meetings with Biden administration

Famed investor Marc Andreessen recently talked about meetings with Biden administration staff who gave him the impression...

EV startup Canoo places remaining employees on a ‘mandatory unpaid break’

Struggling electric van startup Canoo has placed its remaining employees on what it’s calling a “mandatory unpaid...